GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
Creatine does not increase DHT levels or cause hair loss. Personal experiences vary, but scientific evidence shows no link between creatine and hair loss.
A 27-year-old woman with androgenic alopecia is losing hair despite using oral minoxidil and spironolactone, and is considering dutasteride. She is exploring causes like stress and medication side effects, planning tests, and considering treatment changes.
A 21-year-old male experienced initial success with finasteride for 16 months but is now losing hair again. He is considering switching to dutasteride and adding oral minoxidil, while also investigating environmental and health factors.